Resources

 

Clinical Data

 
IMPERIAL Data Sheet

IMPERIAL Data Sheet

View the remarkable results Eluvia achieved in the first head-to-head trial: Eluvia DES vs. Zilver PTX.

 
IMPERIAL Long Lesion Data Sheet

IMPERIAL Long Lesion Sub-Study Data Sheet

Learn more about the 87.9% primary patency Eluvia demonstrated in the IMPERIAL long lesion sub-study (162.8 mm lesion length).

 
IMPERIAL Diabetic Data Sheet

IMPERIAL Diabetic Subgroup Analysis Data Sheet

Learn more about the statistically significant difference in TLR Eluvia demonstrated in the IMPERIAL Diabetic Subgroup Analysis.

 
Hear the full IMPERIAL Trial presentation from the Principal Investigator, William Gray, MD

Dr. William Gray: IMPERIAL Trial

Hear the full IMPERIAL Trial presentation from the Principal Investigator, William Gray, MD.

 
Münster All-Comers Registry

Münster All-Comers Registry

 
MAJESTIC 3-Year Follow-up Data Sheet

MAJESTIC 3-Year Follow-Up Data Sheet

See the unprecedented results of the MAJESTIC trial, which studied stenting of the superficial femoral and/or proximal popliteal artery with the Eluvia Drug-Eluting Stent.

 

Physician Perspectives

 
Expert Panel Discussion

Expert Panel Discussion

Hear in-depth commentary on IMPERIAL, the first head-to-head DES SFA Trial, including key insights and perspectives on how the data will impact treatment of PAD patients.

 
IMPERIAL Trial: FIrst of its Kind Design

IMPERIAL Trial: First of its Kind Design

Physicians provide an overview of the trial’s unique design, including the Eluvia DES and how investigators sought to improve on prior technologies.

 
IMPERIAL Trial: Sustained Release. Superior Results

IMPERIAL Trial Overview

Hear a panel of physicians discuss IMPERIAL’s efficacy and safety results and how they change the landscape of clinical trials.

 
What's Unique about the IMPERIAL Trial?

What's Unique about the IMPERIAL Trial?

Experts share their perspectives on what IMPERIAL’s Kaplan-Meier Primary Patency curves tell them about durability and lack of need for reintervention.

 
Impact of the IMPERIAL Trial

Impact of the IMPERIAL Trial

Hear physician commentary on how the IMPERIAL Trial’s level 1 evidence is influencing their clinical and economic decisions.

 
Eluvia DES: A More Durable Result for Patients

Eluvia DES: A More Durable Result for Patients

Physicians discuss the IMPERIAL Trial from a patient perspective and share how the Eluvia stent may provide a more durable result.

 
IMPERIAL Trial: Influencing Treatment Algorithms

IMPERIAL Trial: Influencing Treatment Algorithms

See how IMPERIAL Trial results may help physicians make recommendations on which forms of antiproliferative therapies are best for each patient.

 
Video showing how the Eluvia Drug-Eluting Stent was designed to address the challenges of the SFA.

The Challenge

Hear what physicians have to say about the challenges of treating the SFA and how drug-eluting stents may help improve patient outcomes.

 
Eluvia Stent engineers finding the right formulation of paclitaxel and polymer for sustained drug release.

The Solution

Physicians talk about the importance of drug-eluting stents in complex lesions and how the Eluvia Drug-Eluting Stent is fine-tuned to produce a sustainable release of paclitaxel over time.

 
Video about the research and development process for the Eluvia Drug-Eluting Vascular Stent System.
 

The Heritage

See how over a decade of research helped Eluvia engineers develop the first drug-eluting stent for the SFA designed to sustain drug release when restenosis is most likely.

 
Stefan Müller-Hülsbeck, MD discusses the unprecedented clinical outcomes for the Eluvia Drug-Eluting Stent.

The Data

See what physicians are saying about the unprecedented clinical outcomes for the Eluvia Drug-Eluting Stent, including two-year primary patency and TLR rates.

 
Dr. William Gray discusses the sustained drug release of the Eluvia Drug-Eluting Vascular Stent System.

The Breakthrough

Physicians discuss the tuned paclitaxel elution profile of the Eluvia Drug-Eluting Stent and how the stent has demonstrated unprecedented efficacy data in patients with peripheral artery disease (PAD).

 
Dr. Juan Granada discusses how sustained drug release sets the Eluvia Stent System apart from other vascular stents.

Dr. Juan Granada: Sustained Drug Release

Dr. Granada explains how sustained paclitaxel release sets Eluvia apart from other drug-eluting stents and helps match the biological needs of peripheral vascular interventions.

 

Design Videos

 
Dr. Jay Kokate discusses the challenges of treating the SFA.

The Challenges of the SFA

Find out how the challenging biological environment, mechanical issues and timing of disease progression impact treatment of the SFA.

 
Video showing how the Eluvia Drug-Eluting Stent was designed to help improve patient outcomes.

The Design of the Eluvia Drug-Eluting Stent System

Discover how the Eluvia Drug-Eluting Stent was designed to match the restenotic cascade for better healing and patency in the superficial femoral arteries (SFA).

 
 
Animation showing how the Eluvia Drug-Eluting Stent was designed to match the unique needs of the SFA.

Eluvia Drug-Eluting Stent Product Animation

Learn more about the biology and timing of restenosis in the SFA, as well as the stent design, drug-elution profile and clinical outcomes data of the Eluvia Drug-Eluting Stent.

 

UPN & GTIN

Eluvia Drug-Eluting Vascular Stent U.S. UPN & GTIN

Eluvia UPN and GTIN

Download Eluvia Drug-Eluting Stent U.S. UPN & GTIN.

 

Product Images

 
 
Downloadable image of the Eluvia Drug-Eluting Stent on a white background.

Eluvia on White

Download an image of the Eluvia Drug-Eluting Vascular Stent System on a white background to use in press materials and more.

 
Downloadable image of the Eluvia Drug-Eluting Stent on a black background.

Eluvia on Black

Download an image of the Eluvia Drug-Eluting Vascular Stent System on a black background to use in press materials and more.

Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Top